Portage Biotech (NASDAQ:ALP) Upgraded to Hold at Zacks Research

Portage Biotech (NASDAQ:ALP – Get Free Report) was upgraded by stock analysts at Zacks Research to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

ALP has been the subject of several other research reports. HC Wainwright started coverage on shares of Portage Biotech in a research report on Monday. They set a “neutral” rating and a $0.25 price target for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Portage Biotech in a research note on Friday, July 24th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Reduce” and an average price target of $0.25.

Get Portage Biotech alerts:

Check Out Our Latest Stock Analysis on ALP

Portage Biotech Price Performance

Shares of Portage Biotech stock opened at $0.15 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.31 and a quick ratio of 0.31. Portage Biotech has a one year low of $0.14 and a one year high of $13.80. The business’s 50 day simple moving average is $0.28 and its two-hundred day simple moving average is $0.34. The stock has a market capitalization of $3.54 million, a P/E ratio of -0.02 and a beta of 0.61.

Portage Biotech (NASDAQ:ALP – Get Free Report) last released its quarterly earnings data on Thursday, July 16th. The company reported $0.48 earnings per share for the quarter. The company had revenue of $0.05 million for the quarter. Analysts forecast that Portage Biotech will post -0.28 EPS for the current year.

Trending Headlines about Portage Biotech

Here are the key news stories impacting Portage Biotech this week:

• Positive Sentiment: HC Wainwright’s $0.25 price target is above Portage Biotech’s recent trading level, suggesting meaningful theoretical upside if the company executes on its development plans. The firm also expects losses to narrow from an estimated $(0.28) per share in fiscal 2027 to $(0.17) in fiscal 2028.
• Neutral Sentiment: HC Wainwright forecasts quarterly losses of $(0.10), $(0.07), $(0.07), and $(0.06) per share for fiscal 2027, resulting in a $(0.28) full-year loss. For fiscal 2028, the analyst projects a relatively consistent $(0.04) quarterly loss and a $(0.17) annual loss, indicating gradual improvement but no expected profitability in the forecast period. Portage Biotech analyst estimates
• Negative Sentiment: The Neutral rating and continuing projected losses may limit investor enthusiasm. Portage Biotech has also experienced substantial share-price weakness, trading close to its one-year low, while its latest reported quarterly revenue was only $0.05 million.

About Portage Biotech

(Get Free Report)

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.

Recommended Stories

• Five stocks we like better than Portage Biotech
• Bloom Energy’s AI Surge Meets a Valuation Reality Check
• Target Is Winning Shoppers Back—Can the Rally Reach $180?
• IonQ’s Space Contract Points to a New Frontier for Quantum Investors
• Is Apple’s AI Strategy Smarter Than Skeptics Think?

Receive News & Ratings for Portage Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portage Biotech and related companies with MarketBeat.com's FREE daily email newsletter.